|
|
|
| Efficacy and toxicity of pemetrexed or docetaxel combined with cisplatin in the first-line treatment of advanced lung adenocarcinoma |
| WANG Hui1,2 and SUN Guoping1 |
1. Department of Oncology, The First Affiliated Hospital of Medical University of Anhui,Hefei 230022,China;
2. Department of Oncology, Ma’anshan People’s Hospital of Anhui Province,Ma’anshan 243000,China |
|
|
|
|
Abstract Objective To compare toxicity and survival of the clinical curative effect of pemetrexed combined with cisplatin and docetaxel combined with cisplatin in the first-line treatment of advanced lung adenocarcinoma with unknown mutations. Methods 70 patients with advanced lung adenocarcinoma, using PP regimen group (pemetrexed + cisplatin) and DP regimen group(docetaxel + cisplatin) treatment respectively. To PP group of 35 cases, intravenous injection of pemetrexed 500 mg/m2 was given on the first day to DP group of 35 cases, on the first day intravenous docetaxel 75 mg/m2 was given. On 2-4 days, the two groups were given combination of cisplatin intravenous infusion of 25 mg/m2. The curative effects and adverse reactions were evaluated 21 days for a cycle, each patient completed at least 2 cycles. Results The median progression free survival was 8 months, and the median survival time was 14.3 months, and the 1 year survival rate was 62.8% in the PP group. The median progression free survival was 7 months, and the median survival time was 13.3 months, and the 1 year survival rate was 65.7% in the DP group. There was no significant difference between the two groups. The incidence of toxicity of hematology, digestive tract and renal function was significantly lower in PP group than in DP group (P<0.05). Conclusions The effect of PP or DP in the treatment of advanced lung adenocarcinoma is similar and the side effect of PP is lower, which is suitable for patients with poor tolerance to chemotherapy.
|
|
Received: 10 June 2015
|
|
|
|
|
|
| [1] |
Eisenhauer A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009,45(2):228-247.
|
| [2] |
Navada S, Lai P, Schwartz AG, et al. Temporal trends in small cell lung cancer:analysis of the national surveillance,epidemiology,and end-results(SEER)database [J]. J Clin Oncol, 2006, 24 (18Suppl): 7082.
|
| [3] |
Ginsberg R J, Goldberg M, Waters P E. Surgery in non-small lung cancer//Roth J A, Ruckdeschel J C, Weisenburger T H. Thoracic Oncology [M]. 2nd ed. Philadelphia: W.B. Saunders Company, 1995:124-146.
|
| [4] |
Alberti W,Anderson G, Bartolucci A.Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials [J]. BMJ, 1995, 311(7010): 899-909.
|
| [5] |
Grossi F, Aita M, Defferrari C,et al. Impact of third-genenration drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach [J]. Oncologist, 2009,14(5):497-510.
|
| [6] |
Adjei A A. Pemetrexed(ALJMTA):a novel multitargeted antineoplastic agent [J]. Clin Cancer Res, 2004,10(2):4276-4280.
|
| [7] |
Scagliotti G V, Parikh P, Joachim V P, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer [J]. J Clin Oncol, 2008, 26(21): 3543-3551.
|
| [8] |
Le Chevalier T, Berille Z, Zaleberg J R, et al. Overview of docetaxel(Taxotere)/cisplain combination in non small cell lung cancer [J]. Semin Oncol, 1999, 26(3 Suppl 11): 13-18.
|
| [9] |
Fossella F, Pereira J R, Von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinationgs versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group [J]. J Clin Oncol, 2003, 21(16): 3016-3024.
|
| [10] |
Pereira J R, Cheng R, Orlando M, et al. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer [J]. Drugs R D, 2013, 13(4):289-296.
|
|
|
|
2016, Vol. 27 
